
Johnson & Johnson announced late-breaking results from the Phase 4 STAR study of TREMFYA in biologic-naive adults with active psoriatic arthritis and axial involvement. TREMFYA met primary and major secondary
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 270.47 | 71.06 | 35.64% |
| Name | Price | % Change | |
|---|---|---|---|
| $270.47 | +35.64% |

Johnson & Johnson announced late-breaking results from the Phase 4 STAR study of TREMFYA in biologic-naive adults with active psoriatic arthritis and axial involvement. TREMFYA met primary and major secondary

JPMorgan raised the firm’s price target on Johnson & Johnson to $300 from $285 and keeps a Neutral rating on the shares as part of an analyst day preview. The

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, trial results and a psilocybin shipment. QUARTERLY EARNINGS: On Friday, GH

Johnson & Johnson announced that Memorial Hermann-Texas Medical Center in Houston, Texas will be the first hospital to install the OTTAVA Robotic Surgical System, representing a major milestone in the

Johnson & Johnson announced the submission of a supplemental New Drug Application to the U.S. FDA seeking the approval of caplyta for the treatment of manic or mixed episodes associated

BofA raised the firm’s price target on Johnson & Johnson to $292 from $275 and keeps a Neutral rating on the shares. The company enters its December 8th Enterprise Business

The major averages were lower near noon amid weakness in tech stocks as investors await Nvidia’s earnings report and a potentially record-setting IPO of Anthropic this week. Traders continue to

Blackstone (BX) announced that funds managed by Blackstone Life Sciences will provide $750M in development funding to Johnson & Johnson (JNJ) to support the Phase 3 clinical development of OLN324,

Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential

Oppenheimer lowered the firm’s price target on Alumis (ALMS) (ALMS to $28 from $37 and keeps an Outperform rating on the shares after the company reported Q3 results along with
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Assigned | Nov 20, 2026 | ||||
| buy | Reiterated | Nov 17, 2026 | ||||
| hold | Reiterated | Nov 17, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Oct 26, 2026 | ||||
| buy | Reiterated | Oct 25, 2026 | ||||
| hold | Downgraded | Oct 21, 2026 | ||||
| buy | Reiterated | Oct 15, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Jan 26, 2027Before Open | $643.09B | $2.91 | $26.40B | 0.21 | 41.01 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.